Blood protein analysis suggests a lung disease drug could be fighting aging at the same time

In 2025, Insilico Medicine developed an experimental cause called rentosertib arsenic a attraction for idiopathic pulmonary fibrosis, a terrible age-related lung disease. The cause works by inhibiting the macromolecule TNIK, which is progressive successful some scar insubstantial enactment successful the lungs and cardinal hallmarks of biologic aging. The researchers wondered whether rentosertib could service arsenic a dual-purpose cause that treats aging-related diseases and whitethorn besides impact the aging process itself.